Related Experiment Videos
Antigenic cross-reactivity among Porphyromonas gingivalis serotypes
1Department of Periodontics, School of Dentistry, University of Washington, Seattle, USA.
Oral Microbiology and Immunology
|January 12, 2001
Summary
This study investigated shared antigens in Porphyromonas gingivalis serotypes for vaccine development. Key protein components were identified, showing potential as cross-reactive vaccine candidates against this bacterium.
Area of Science:
- Microbiology
- Immunology
- Vaccinology
Background:
- Porphyromonas gingivalis is a key pathogen in periodontitis.
- Developing a broadly protective vaccine requires identifying antigens common across diverse serotypes.
- Previous research has not fully elucidated the antigenic cross-reactivity among P. gingivalis serotypes.
Purpose of the Study:
- To evaluate the antigenic cross-reactivity among P. gingivalis serotypes A-D.
- To identify shared antigenic components for potential vaccine development.
Main Methods:
- Antibodies were generated in rabbits against intact cells of P. gingivalis strains representing serotypes A-D.
- Antigenic cross-reactivity was assessed using enzyme-linked immunosorbent assay (ELISA) and Western blotting.
- Functional assays included opsonization, phagocytosis, and killing by polymorphonuclear leukocytes.
Main Results:
- ELISA and Western blots revealed extensive antigenic cross-reactivity among serotypes, with shared protein components identified at approximately 140, 130, 37, 32, and 28 kDa.
- A variable molecular mass smear, likely lipopolysaccharide and carbohydrates, was also shared.
- Functional assays indicated varying degrees of opsonization and killing, with some shared antigens demonstrating cross-protective potential.
Conclusions:
- Several protein components (140, 130, 37, 28 kDa) are shared across P. gingivalis serotypes A-D.
- These shared antigens represent promising candidates for a P. gingivalis vaccine.
- Further research is warranted to validate these antigens in a vaccine formulation.